SHUKRA MEDTECH's (NSE:SHUKRAPHAR) Earnings Are Weaker Than They Seem
SHUKRA MEDTECH LIMITED's (NSE:SHUKRAPHAR) robust earnings report didn't manage to move the market for its stock. We did some digging, and we found some concerning factors in the details.
Examining Cashflow Against SHUKRA MEDTECH's Earnings
In high finance, the key ratio used to measure how well a company converts reported profits into free cash flow (FCF) is the accrual ratio (from cashflow). In plain english, this ratio subtracts FCF from net profit, and divides that number by the company's average operating assets over that period. The ratio shows us how much a company's profit exceeds its FCF.
As a result, a negative accrual ratio is a positive for the company, and a positive accrual ratio is a negative. That is not intended to imply we should worry about a positive accrual ratio, but it's worth noting where the accrual ratio is rather high. To quote a 2014 paper by Lewellen and Resutek, "firms with higher accruals tend to be less profitable in the future".
Over the twelve months to September 2026, SHUKRA MEDTECH recorded an accrual ratio of 0.79. As a general rule, that bodes poorly for future profitability. To wit, the company did not generate one whit of free cashflow in that time. Over the last year it actually had negative free cash flow of ₹288m, in contrast to the aforementioned profit of ₹443.2m. Coming off the back of negative free cash flow last year, we imagine some shareholders might wonder if its cash burn of ₹288m, this year, indicates high risk.
Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of SHUKRA MEDTECH.
Our Take On SHUKRA MEDTECH's Profit Performance
As we have made quite clear, we're a bit worried that SHUKRA MEDTECH didn't back up the last year's profit with free cashflow. As a result, we think it may well be the case that SHUKRA MEDTECH's underlying earnings power is lower than its statutory profit. But the good news is that its EPS growth over the last three years has been very impressive. Of course, we've only just scratched the surface when it comes to analysing its earnings; one could also consider margins, forecast growth, and return on investment, among other factors. If you'd like to know more about SHUKRA MEDTECH as a business, it's important to be aware of any risks it's facing. Every company has risks, and we've spotted 1 warning sign for SHUKRA MEDTECH you should know about.
This note has only looked at a single factor that sheds light on the nature of SHUKRA MEDTECH's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. Some people consider a high return on equity to be a good sign of a quality business. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.